| 1.55 -0.02 (-1.27%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.25 | 1-year : | 2.55 |
| Resists | First : | 1.93 | Second : | 2.18 |
| Pivot price | 1.8  |
|||
| Supports | First : | 1.51 | Second : | 1.26 |
| MAs | MA(5) : | 1.57 |
MA(20) : | 1.86 |
| MA(100) : | 1.91 |
MA(250) : | 1.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 4.3 |
| RSI | RSI(14): 31.6 |
|||
| 52-week | High : | 2.66 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALXO ] has closed above bottom band by 13.2%. Bollinger Bands are 17.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.62 - 1.63 | 1.63 - 1.64 |
| Low: | 1.5 - 1.51 | 1.51 - 1.52 |
| Close: | 1.53 - 1.55 | 1.55 - 1.57 |
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology firm focused on developing innovative therapies for cancer patients. At the forefront of its pipeline is ALX148, a CD47 blocking therapeutic, which is progressing through Phase 1b/2 clinical trials. This candidate is being evaluated for a variety of hematologic malignancies, including myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin's lymphoma. Additionally, it targets a range of solid tumors, such as head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumor indications. Beyond its lead candidate, ALX Oncology's pre-clinical portfolio includes ALTA-002, a SIRPa TRAAC designed to engage both the innate and adaptive immune systems in the fight against cancer. The company maintains a robust network of strategic collaborations, including a Phase 2 trial with Merck evaluating ALX148 in combination with pembrolizumab (with or without chemotherapy) for head and neck cancer. Another partnership involves Zymeworks for a Phase 1 trial assessing ALX148 alongside the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors. Furthermore, ALX Oncology collaborates with Tallac Therapeutics for the development, manufacturing, and commercialization of a novel class of cancer immunotherapeutics. Further bolstering its capabilities are licensing agreements with Selexis SA and Crystal Bioscience, Inc. Founded in 2015, the company operates from its headquarters in South San Francisco, California.
Fri, 05 Jun 2026
ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Chart - ChartMill
Thu, 04 Jun 2026
Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15% - simplywall.st
Wed, 03 Jun 2026
ALXO: Evorpacept and ALX2004 advance with strong data, robust funding, and pivotal trials planned - TradingView
Wed, 03 Jun 2026
ALXO: Evorpacept and ALX2004 advance with strong data, targeting high unmet needs and pivotal trials ahead - TradingView
Mon, 01 Jun 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York - GlobeNewswire
Wed, 27 May 2026
ALX Oncology (ALXO) Lightstone group falls below 5% ownership - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 135 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 78.7 (%) |
| Shares Short | 1,380 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.8 % |
| Return on Equity (ttm) | -74.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -1.05 |
| PEG Ratio | 0 |
| Price to Book value | 1.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|